Novan to Present Antiviral Preclinical Results of Nitric Oxide-Releasing Drug Candidates for the Treatment of Papillomavirus
Abstract Accepted for Presentation at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy September 8, 2014
DURHAM, N.C. (August 14, 2014) - Novan Therapeutics, a clinical stage biotech company focused on advancing nitric oxide therapies, announced today that antiviral data from a preclinical animal study has been accepted for presentation at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 5-9, 2014, in Washington, DC.
Presentation Number V-1822a: “Antiviral Efficacy of Nitric Oxide-Releasing Drug Candidates In Vivo Utilizing the Cottontail Rabbit Papillomavirus Model,” K. Coggan, K. Balogh, S. Hollenbach, N. Christensen, and N. Stasko
Presenter: Kimberly Coggan, PhD, Molecular Microbiologist, Novan Therapeutics
Session Date, Time and Location: Monday, September 8, 2014; 11:00 a.m. – 1:00 p.m. EDT; Exhibit Hall B
About Novan, Inc.
Novan Therapeutics is a privately-held, clinical stage biotech company focused on advancing nitric oxide therapies. Nitric oxide, one of the most studied molecules in human physiology, has been shown to exhibit antimicrobial activity and to promote vasodilation, regulate inflammation, stimulate tissue repair, and eradicate cancer cells. Novan’s core technologies solve the previous delivery issues with nitric oxide by stably storing the gaseous species on macromolecules that result in a diverse pipeline of “timed-release” nitric oxide-releasing new chemical entities. The company's proprietary platform technology enables drugable nitric oxide in a variety of dosage forms.
To learn more about Novan Therapeutics, please visit www.novantherapeutics.com.
Julia Brannan, Pascale Communications, LLC, on behalf of Novan Therapeutics